Obesity Management

This episode explores the launch and accessibility of FDA-approved oral GLP-1 orforglipron, including availability through Amazon Pharmacy's same-day delivery service.

Although the approval does not permit entrance into the market, this decision marks an important step to more universally accessible GLP-1 RAs.

Catch up on FDA decisions, new GLP-1 agonists, and more.

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

Stay updated with the latest healthcare breakthroughs, including FDA actions and comparative weight loss drug data, in this week’s essential news roundup.

Check out 6 FDA decisions to watch in Q2 2026, listed chronologically by expected decision date.

Indirect data suggest oral semaglutide may reduce weight more than orforglipron, but cross-trial comparisons limit clinical interpretation.

This episode addresses the groundbreaking approval of the first GLP-1 RA without timing or meal restrictions.

The Agency approved Lilly’s orforglipron (Foundayo) for adults with obesity or overweight. It can be taken any time of the day without restrictions on food and water intake.

A metabolic polygenic risk score built from 20 traits and more than 8.5 million individuals outperformed existing disease-prediction models.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new phase 3 data, in this week’s essential news roundup.

FDA clears setmelanotide for acquired hypothalamic obesity for ages 4 years and older, delivering 15.8% BMI drop in TRANSCEND.

The approval is based on results from the STEP UP trial program showing substantial weight loss in adults with obesity.

Data from the ACCESS II trial, ACCESS extension study, and a body composition study provide an early look at efficacy and safety data of a new investigational oral GLP-1.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new trial data, in this week’s essential news roundup.

Tozzi and Wallach discuss ways to omit artificial sweeteners and added sugars from children’s diets and minimize risk for T2D and MASLD later in life.

Alexander discusses his recent study comparing 61 trials of 4 main GLP-1 RAs, highlighting their increased efficacy for weight loss in female patients.

Budini discusses his recent study investigating the trajectory of weight regain after GLP-1 cessation, given current high discontinuation rates.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss topline results from the TRIUMPH-4 trial, demonstrating retatrutide's efficacy in promoting weight loss.

This World Obesity Day, catch up on major paradigm shifts in the diagnosis, discussion, and treatment of obesity, one of the world’s most devastating chronic diseases.

Catch up with FDA decisions, key trial results, podcast updates, and more.

Isaacs and Bellini discuss recent updates on Eli Lilly's orforglipron and retatrutide and Novo Nordisk's UBT251, along with other recent GLP-1 news.

Systematic review identifies patient and clinician barriers to obesity management before kidney transplantation, with Adrian Brown, PhD.

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval and what it means for Wegovy 7.2 mg in the US.